Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 11.

Safroneeva, E; Vavricka, S R; Fournier, N; Pittet, V; Peyrin-Biroulet, L; Straumann, A; Rogler, G; Schoepfer, A M; Braegger, C; Swiss IBD Cohort Study Group (2015). Impact of the early use of immunomodulators or TNF antagonists on bowel damage and surgery in Crohn's disease. Alimentary Pharmacology & Therapeutics, 42(8):977-989.

Biedermann, L; Fournier, N; Misselwitz, B; Frei, P; Zeitz, J; Manser, C N; Pittet, V; Juillerat, P; von Känel, R; Fried, M; Vavricka, S R; Rogler, G (2015). High rates of smoking especially in female Crohn's disease patients and low use of supportive measures to achieve smoking cessation-data from the swiss IBD cohort study. Journal of Crohn's & colitis, 9(10):819-829.

Seibold, F; Fournier, N; Beglinger, C; Mottet, C; Pittet, V; Rogler, G (2014). Topical therapy is underused in patients with ulcerative colitis. Journal of Crohn's & colitis, 8(1):56-63.

Scharl, M; Mwinyi, J; Fischbeck, A; Leucht, K; Eloranta, J J; Arikkat, J; Pesch, T; Kellermeier, S; Mair, A; Kullak-Ublick, G A; Truninger, K; Noreen, F; Regula, J; Gaj, P; Pittet, V; Mueller, C; Hofmann, C; Fried, M; McCole, D F; Rogler, G (2012). Crohn's disease-associated polymorphism within the PTPN2 gene affects muramyl-dipeptide-induced cytokine secretion and autophagy. Inflammatory Bowel Diseases, 18(5):900-912.

Vavricka, S R; Spigaglia, S M; Rogler, G; Pittet, V; Michetti, P; Felley, C; Mottet, C; Braegger, C P; Rogler, D; Straumann, A; Bauerfeind, P; Fried, M; Schoepfer, A M (2011). Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease. Inflammatory Bowel Diseases, 18(3):496-505.

Braegger, C P; Ballabeni, P; Rogler, D; Vavricka, S R; Friedt, M; Pittet, V (2011). Epidemiology of inflammatory bowel disease: Is there a shift towards onset at a younger age? Journal of Pediatric Gastroenterology and Nutrition, 53(2):141-144.

Vavricka, S R; Brun, L; Ballabeni, P; Pittet, V; Prinz Vavricka, B M; Zeitz, J; Rogler, G; Schoepfer, A M (2011). Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. American Journal of Gastroenterology, 106(1):110-119.

Pittet, V; Juillerat, P; Michetti, P; Vader, J P; Burnand, B; Rogler, G; Beglinger, C; Seibold, F; Mottet, C; Felley, C; Gonvers, J J; Froehlich, F; et al; Braegger, C P (2010). Appropriateness of therapy for fistulizing Crohn's disease: findings from a national inflammatory bowel disease cohort. Alimentary Pharmacology & Therapeutics, 32(8):1007-1016.

Juillerat, P; Pittet, V; Vader, J P; Burnand, B; Gonvers, J J; de Saussure, P; Mottet, C; Seibold, F; Rogler, G; Sagmeister, M; Felley, C; Michetti, P; Froehlich, F; et al; Braegger, C P (2010). Infliximab for Crohn's disease in the Swiss IBD Cohort Study: clinical management and appropriateness. European Journal of Gastroenterology & Hepatology, 22(11):1352-1357.

Voegtlin, M; Vavricka, S R; Schoepfer, A M; Straumann, A; Voegtlin, J; Rogler, G; Ballabeni, P; Pittet, V; Buser, A; Fried, M; Beglinger, C (2010). Prevalence of anaemia in inflammatory bowel disease in Switzerland: a cross-sectional study in patients from private practices and university hospitals. Journal of Crohn's and Colitis, 4(6):642-648.

Pittet, V; Juillerat, P; Mottet, C; Felley, C; Ballabeni, P; Burnand, B; Michetti, P; Vader, J P (2009). Cohort profile: the Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS). International Journal of Epidemiology, 38:922-931.

This list was generated on Wed Sep 20 22:37:53 2017 CEST.